Evidence mapPaperPMID 42298951Full record

ReviewOxidative medicine and cellular longevity2026

Pathological Interplay of ROS With Myofibroblasts: An Impediment to Corneal Restitution.

Mohammad Yahya Karimi, Abasalt Hosseinzadeh Colagar

Abstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohammad Yahya KarimiDepartment of Molecular and Cell Biology, Faculty of Basic Science, University of Mazandaran, Babolsar, Iran, umz.ac.ir.ORCID https://orcid.org/0009-0007-3080-7576
Abasalt Hosseinzadeh ColagarDepartment of Molecular and Cell Biology, Faculty of Basic Science, University of Mazandaran, Babolsar, Iran, umz.ac.ir.ORCID https://orcid.org/0000-0001-6536-8250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myofibroblasts are morphologically similar cells with diverse origins that exhibit characteristics of both fibroblasts and smooth muscle cells. Following insults, myofibroblasts play critical roles in tissue reintegration and restitution. However, their prolonged presence and activity impede physiological recovery, leading to persistent or progressive tissue complications, as evidenced in corneal fibrosis and opacification. Reactive oxygen species (ROS) are key signaling intermediates in various cellular events, playing critical roles in the physiology of myofibroblasts. However, when dysregulated, these molecules can engage in misinstructive manners with myofibroblasts, directing these cells toward pathogenic states and behaviors. In brief, dysregulated ROS pathologically modulate myofibroblast differentiation, extracellular matrix (ECM) remodeling, and immune evasion, maintaining self-perpetuating cycles of myofibroblast survival. The mediation of ROS promotes maladaptive intra and extracellular responses that contribute to myofibroblast persistence by enhancing ECM stiffness, increasing resistance to apoptosis, inducing senescence, and impairing immune clearance. ROS-mediated alterations in ECM components, most notably in proteoglycans (PGs) and glycosaminoglycans (GAGs), further dysregulate the ECM and make it more conducive to myofibroblast persistence. Additionally, ROS-induced immune privilege mechanisms prevent the proper clearance of myofibroblasts. Therefore, targeting ROS collectively offers promising therapeutic potential for mitigating their pathological presence and behavior, thereby enhancing overall corneal recovery following insults.

Indexed as

CorneaMyofibroblastsReactive Oxygen SpeciesAnimalsExtracellular MatrixHumansReactive Oxygen Speciescorneahealingmyofibroblastpathogenesisreactive oxygen species

Identifiers

PMID42298951
PMCPMC13269850

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.